Literature DB >> 20156099

Differential effects of P-class versus other CpG oligodeoxynucleotide classes on the impaired innate immunity of plasmacytoid dendritic cells in HIV type 1 infection.

Norbert Donhauser1, Martin Helm, Kathrin Pritschet, Philipp Schuster, Moritz Ries, Klaus Korn, Jörg Vollmer, Barbara Schmidt.   

Abstract

Abstract Human plasmacytoid dendritic cells (PDC) are the major producers of type I interferons (IFN) after stimulation with CpG oligodeoxynucleotides (ODN). HIV-1-infected patients show a deficit in PDC numbers and function with progression of disease. CpG ODN appear to be attractive therapeutics to support the impaired innate immunity in HIV-1 infection. PDC counts, phenotype, and function were analyzed in 23 HIV-infected untreated individuals and 16 controls. Markers for migration (CCR7), activation (CD80), maturation (CD83), and endocytosis (BDCA2) were evaluated at baseline and 20 h after in vitro stimulation with class A, B, C, and P ODN. PDC counts and the expression of BDCA2 on these cells were significantly lower in HIV-1-infected subjects compared to controls (both p < 0.001). After stimulation with CpG ODN, CD80 and CD83 were upregulated to a similar extent in patients and controls, whereas CCR7 was upregulated more efficiently by CpG-P and CpG-C than CpG-A in HIV-1-infected individuals compared to controls. The IFN-alpha induction significantly differed for the CpG ODN classes (A > P > C > B) in patients and controls (p < 0.05). Functional PDC deficits in IFN-alpha and TNF-alpha induction were particularly evident in subjects with less than 500 CD4(+) cells/mul. CpG-P ODNs not only induced remarkable IFN-alpha production in patient PBMCs, but also significantly upregulated the antibacterial and antiviral CXC chemokine IP-10. In conclusion, PDC counts, phenotype, and function are significantly impaired in HIV-1-infected subjects. Optimized P-class ODN may be effective in reversing this innate immune defect, which should be further evaluated in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156099     DOI: 10.1089/aid.2008.0278

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  HIV delays IFN-α production from human plasmacytoid dendritic cells and is associated with SYK phosphorylation.

Authors:  Calvin C Lo; Jordan A Schwartz; Dylan J Johnson; Monica Yu; Nasra Aidarus; Shariq Mujib; Erika Benko; Martin Hyrcza; Colin Kovacs; Mario A Ostrowski
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

Review 2.  Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation.

Authors:  Moritz Ries; Kathrin Pritschet; Barbara Schmidt
Journal:  Clin Dev Immunol       Date:  2011-11-29

3.  Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction.

Authors:  Norbert Donhauser; Kathrin Pritschet; Martin Helm; Thomas Harrer; Philipp Schuster; Moritz Ries; Georg Bischof; Jörg Vollmer; Sigrun Smola; Barbara Schmidt
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

4.  A plasmid containing CpG ODN as vaccine adjuvant against grass carp reovirus in grass carp Ctenopharyngodon idella.

Authors:  Hang Su; Zhiwei Liao; Gailing Yuan; Jianguo Su
Journal:  Oncotarget       Date:  2017-09-23

Review 5.  CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.

Authors:  Zhongkun Zhang; Jimmy Chun-Tien Kuo; Siyu Yao; Chi Zhang; Hira Khan; Robert J Lee
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.